EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 14 October 2021

Securing and strengthening Europe's position as leader in life sciences for the benefit of patients across the world

By Olivier Laureau, President of Servier and Second Vice President of EFPIA

Since the beginning of 2020, the world has experienced an unprecedented health crisis. In the early stages of pandemic our only defense was extreme lockdown measures to protect citizens from the spread of the virus. Very quickly attention turned to the life science community to develop diagnostics, therapeutics and vaccines, and mitigate the human, economic and social harm that COVID-19 had caused world-wide.

The research-based pharmaceutical industry responded to this crisis at an extraordinary pace, developing safe and effective vaccines in an incredibly short time-frame. The response underlined the need for a strong pharmaceutical sector, able to (...)

Read more

News

EFPIA statement on tomorrow's meeting of EU Health Ministers
11 October 2021

EFPIA welcomes the proposals from the the Slovenian Presidency of the Council of the EU presented in the draft Council... Read more

Blogs

‘Moonshot’ mindset can make the impossible possible
14 October 2021 - Nathalie Moll

Over the last 20 years we have witnessed some incredible advances in orphan and paediatric medicine. Now is the time... Read more

Multi-stakeholder dialogue paving the way to increased understanding of complex clinical trials...
14 October 2021 - Nick Sykes - Chrissie Fletcher - Mireille Muller

Highlights from the 5-6 October Workshop Read more

IMI projects deliver top quality research publications
14 October 2021 - Magda Chlebus

Collaboration counts: the Innovative Medicines Initiative (IMI) drove public-private partnerships that produced high-impact... Read more

Podcast: What is needed from the ECDC to be better prepared for future health threats?
14 October 2021

Welcome to 19 Conversations Read more

How can we make the impossible possible for rare and paediatric disease?

EFPIA's recent event
This virtual event sought to discuss challenges and facilitators in the development of orphan and paediatric medicines.... Read more

Karl's story
30 million people in Europe live with a rare disease. #WeWontRest in finding ground-breaking therapies that make more... Read more

How has the Orphan Regulation contributed to addressing unmet medical needs for rare diseases?
Hear from David Nestor, Head of Neuromuscular Diseases, Europe, Canada and Partner Markets, Biogen Read more

Making the impossible possible for children
With 600 paediatric medicines in development, we’ve made great strides towards paediatric research and #WeWontRest driving... Read more

Events

Living with Cancer after Cancer
20 October 2021 (Virtual event)

The 1st International Conference on Cancer Survivorship Read more

Global Pharmaceutical and Biotechnology Conference
08 November 2021 (Virtual event)

Sustaining innovation and collaboration beyond the pandemic #FTPharma Read more

Investigating the syndemic threat of COVID-19 and chronic disease: The diabetes case
09 November 2021 (Virtual event)

Improved integration of care is the way forward to strengthen chronic disease management in emergencies and beyond Read more

Pandemic Prevention: how Europe can lead the fight against AMR
16 November 2021 (Virtual event)

The COVID-19 pandemic took the world by surprise. An AMR induced pandemic will not. Read more

What we are reading

Harmonised Newborn Screening in Europe - a window of opportunity that we should not miss!
On 12 October 2021 (EURORDIS)

A harmonised approach to newborn screening is the only way to ensure children across Europe undergo the most comprehensive... Read more

Calling decision-makers to adapt flu vaccination programs and policies in light of COVID-19...
On 15 September 2021 (Together against Flu)

IFPMA and The Health Policy Partnership have launched a report ‘Influenza vaccination during the COVID-19 pandemic –... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu